Genomics and the future of psychopharmacology: MicroRNAs offer novel therapeutics

Research output: Contribution to journalArticlepeer-review


MicroRNAs (miRNAs) are short, noncoding RNAs functioning as regulators of the transcription of protein-coding genes in eukaryotes. During the last two decades, studies on miRNAs indicate that they have potential as diagnostic and prognostic biomarkers for a wide range of cancers. Research interest in miRNAs has moved to embrace further medical disciplines, including neuropsychiatric disorders, comparing miRNA expression and mRNA targets between patient and control blood samples and postmortem brain tissues, as well as in animal models of neuropsychiatric disorders. This manuscript reviews recent findings on miRNAs implicated in the pathology of mood disorders, schizophrenia, and autism, as well as their diagnostic potential, and their potential as tentative targets for future therapeutics. The plausible contribution of X chromosome miRNAs to the larger prevalence of major depression among women is also evaluated.

Original languageEnglish
Pages (from-to)131-138
Number of pages8
JournalDialogues in Clinical Neuroscience
Issue number2
StatePublished - 2019


  • Autism spectrum disorder
  • Bipolar disorder
  • Major depressive disorder
  • MicroRNA
  • Neuroplasticity
  • Schizophrenia
  • X chromosome inactivation


Dive into the research topics of 'Genomics and the future of psychopharmacology: MicroRNAs offer novel therapeutics'. Together they form a unique fingerprint.

Cite this